Trial Profile
A Phase 3, Multicenter, Open-label, Sevelamer Hydrochloride-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia on Hemodialysis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Bixalomer (Primary) ; Sevelamer
- Indications Hyperphosphataemia; Renal failure
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 22 Dec 2014 New trial record